Andrea I. McClatchey

• 
  www.ctf.org/For-Scientists/ddi-nf-preclinical-consortiu - [Cached Version]
  Published on: 10/17/2009    Last Visited: 10/17/2009  

  Director: Andrea McClatchey, Ph.D.

• 
  www.ctf.org/for-scientists/medical-affairs-committee-20 - [Cached Version]
  Published on: 1/1/2008    Last Visited: 2/13/2009  

  Andrea I. McClatchey, Ph.D., (Co-Chair RAB) Harvard Medical School

• 
  www.ctf.org/For-Scientists/ddi-awards.html - [Cached Version]
  Published on: 8/31/2009    Last Visited: 10/17/2009  

  Andrea McClatchey, Ph.D., Harvard Medical School/Massachusetts General Hospital
  ...
  Andrea McClatchey, Ph.D., Harvard Medical School/Massachusetts General Hospital

• 
  www.ctf.org/for-scientists/january-2007-awardees.html - [Cached Version]
  Published on: 1/1/2007    Last Visited: 2/13/2009  

  Andrea McClatchey, Ph.D. Harvard Medical School/Massachusetts General Hospital
  ...
  Dr. McClatchey's laboratory will examine at whether EGFR-targeted drugs are potential treatments of NF2 tumors.

• 
  www.elso.org/index.php?id=conferences&ListID=95 - [Cached Version]
  Published on: 10/6/2006    Last Visited: 5/26/2008  

  Andrea McClatchley - Harvard Medical School, USA

• 
  www.ctf.org/for-scientists/research-advisory-board-rab- - [Cached Version]
  Published on: 1/1/2008    Last Visited: 2/13/2009  

  Dr. Andrea I. McClatchey Harvard Medical School / MGH Cancer Center

• 
  2005 Annual Meeting - American Association for Cancer... - [Cached Version]
  Published on: 11/20/2004    Last Visited: 12/19/2004  

  Andrea I. McClatchey, Massachusetts General Hospital Cancer Center, Charlestown, MA
  ...
  Andrea I. McClatchey, Massachusetts General Hospital Cancer Center, Charlestown, MA

• 
  2005 GRC on Cell Contact & Adhesion - [Cached Version]
  Published on: 6/13/2005    Last Visited: 11/9/2005  

  Andrea McClatchey (Harvard University)

• 
  Archived Newsletters - Publications - Summer 1998 - [Cached Version]
  Published on: 7/1/1998    Last Visited: 6/7/2004  

  Dr. Andrea McClatchey Harvard Medical School/MGH
  ...
  Dr. McClatchey will study the function of the NF2 protein in the mouse model to determine what role it plays in the signaling pathway that determines cell growth and differentiation.She suspects that the role of the NF2 tumor suppressor and the family of proteins to which it belongs play a much more important role in human cancer development and progression than suspected.
  ...
  NF2 mouse models were described by Dr. Marco Giovannini (CEPH Fondation Jean Dausset, France) and Dr. Andrea McClatchey (Harvard/MGH).
  ...
  McClatchey reported that Nf2 +/- mice develop osteosarcomas, fibrosarcomas, and hepatocellular carcinomas, in contrast with the human disorder.

• 
  Bio.com -- Biotech, Biotechnology and Pharmaceutical... - [Cached Version]
  Published on: 5/2/2003    Last Visited: 5/6/2003  

  "Since merlin is a tumor suppressor whose loss of function leads to tumor development, it is absolutely critical to define what happens when this function is lost," says Andrea McClatchey, PhD, of the MGH Cancer Center, the senior author of the current report."Our objective was to define the primary cellular and molecular consequences of that loss of function."
  
  McClatchey and her colleagues had previously developed a strain of mice genetically engineered to lack normal Nf2 genes.
  ...
  "Our study suggests that, through its link to the cellular cytoskeleton, merlin normally organizes the structure that facilitates cell-to-cell communication - the adherens junction," says McClatchey, who is an assistant professor of Pathology at Harvard Medical School.
  ...
  "Given that loss of adherens junctions has been linked to both tumor initiation and tumor metastasis," says McClatchey, "loss of NF2 may be an example of an event that both starts a tumor and confers metastatic potential."

Page:  1 2